Updates

Explore Medicines360’s latest news and resources

Blog

Provider Snapshot: Erie Family Health Centers

Over the past year, Medicines360’s impact team has been busy interviewing and surveying hundreds of healthcare providers and administrators to understand how our hormonal IUD’s low 340B price has affected clinics and patients. This research provides us with valuable data that we are using to refine our strategy and maximize our social impact. Sometimes, we […]

Read More >
Blog

Measuring Our Impact

When women can access affordable contraception, they can live their best and fullest lives. As part of our pioneering non-profit pharmaceutical business model, Medicines360 offers its hormonal IUD at a deeply discounted price to clinics participating in the 340B Drug Pricing Program. A key component of measuring our impact is determining how this price affects […]

Read More >
Press Releases

Newly Published Data from Phase 3 Clinical Trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Reinforces Efficacy for Longest-Approved Duration of Use for a Hormonal IUS

SAN FRANCISCO – December 17, 2019 – Medicines360, a global nonprofit women’s health pharmaceutical company, announced newly published data finding that LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg is highly efficacious in preventing pregnancy for up to six years of use. The publication also reports data related to the bleeding profile over the same period of […]

Read More >
Blog

Pioneering the Nonprofit Pharmaceutical Industry

Medicines360 is a nonprofit women’s health pharmaceutical company in San Francisco. As a nonprofit, we answer to our mission: to remove cost as a barrier to health by developing and providing quality, affordable women’s health products. We were founded in 2009 and brought our first product, a hormonal intrauterine device (IUD) called Liletta®, to the […]

Read More >
Press Releases

FDA Approves Medicines360’s LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs

SAN FRANCISCO and DUBLIN – Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA® (levonorgestrel-releasing […]

Read More >

FEATURED UPDATES

News

International Women’s Day at Direct Relief International

SANTA BARBARA INDEPENDENT – Direct Relief’s Kirchmaier Volunteer Center was standing room only Friday morning, March 8, as more than 150 people gathered in honor of International Women’s Day to celebrate achievements and acknowledge remaining hurdles, including the lack of global access to affordable maternal health care. This year’s theme was “balance for better — […]

Read More >
Press Releases

Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs) SAN FRANCISCO and CHARLESTON, S.C. – Medicines360 and Afaxys Pharma, LLC, two mission-driven, socially conscious women’s health pharmaceutical companies, today announced their collaboration to promote Medicines360’s intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, which is […]

Read More >
News

Medicines360 Expands Access To Contraception In Africa

FORBES – Medicines360, the non-profit pharmaceutical company behind the hormonal IUD Liletta, is on a mission to increase women’s access to reproductive care around the world. This month, the female-led company announced the launch of Avibela, a hormonal IUD, in Madagascar.

Read More >